SG117434A1 - Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease - Google Patents

Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Info

Publication number
SG117434A1
SG117434A1 SG200300701A SG200300701A SG117434A1 SG 117434 A1 SG117434 A1 SG 117434A1 SG 200300701 A SG200300701 A SG 200300701A SG 200300701 A SG200300701 A SG 200300701A SG 117434 A1 SG117434 A1 SG 117434A1
Authority
SG
Singapore
Prior art keywords
alpha
inhibitors
integrin receptor
tgf
kidney disease
Prior art date
Application number
SG200300701A
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town Nat Res Hospital filed Critical Boys Town Nat Res Hospital
Publication of SG117434A1 publication Critical patent/SG117434A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200300701A 1998-05-22 1999-05-19 Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease SG117434A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09

Publications (1)

Publication Number Publication Date
SG117434A1 true SG117434A1 (en) 2005-12-29

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200300701A SG117434A1 (en) 1998-05-22 1999-05-19 Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Country Status (21)

Country Link
EP (1) EP1079843B1 (cs)
JP (1) JP2002516287A (cs)
CN (1) CN1187084C (cs)
AT (1) ATE359804T1 (cs)
BR (1) BR9911067A (cs)
CA (1) CA2329757C (cs)
CZ (1) CZ296262B6 (cs)
DE (1) DE69935853T2 (cs)
DK (1) DK1079843T3 (cs)
EA (1) EA004145B1 (cs)
EE (1) EE04581B1 (cs)
ES (1) ES2285841T3 (cs)
HU (1) HUP0202048A3 (cs)
NO (1) NO20005883L (cs)
NZ (1) NZ508317A (cs)
PL (1) PL345946A1 (cs)
PT (1) PT1079843E (cs)
SG (1) SG117434A1 (cs)
SI (1) SI1079843T1 (cs)
TR (1) TR200003432T2 (cs)
WO (1) WO1999061040A2 (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146508A0 (en) 1999-06-01 2002-07-25 Biogen Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
WO2001066140A1 (en) * 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
PL376714A1 (pl) 2002-11-01 2006-01-09 Boys Town National Research Hospital Indukowalny ligand Ó1ß1 integryny i zastosowania
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
MX2008014793A (es) 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
PE20142404A1 (es) 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
WO2022076452A1 (en) * 2020-10-05 2022-04-14 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
US20250049806A1 (en) * 2021-11-12 2025-02-13 Ube Corporation Pharmaceutical composition for providing treatment for or preventing alport syndrome
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011718A1 (en) * 1995-09-27 1997-04-03 The Victoria University Of Manchester Inhibitors of integrin receptors and their therapeutical uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011718A1 (en) * 1995-09-27 1997-04-03 The Victoria University Of Manchester Inhibitors of integrin receptors and their therapeutical uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL ADHESION AND COMMUNICATION 1995. VOL 3, NO. 3, PAGES 187-200 *
DEV. BIOL., 1996. VOL. 175, NO. 2, PAGES 301-313 *
GENES AND DEVELOPMENT 1996. VOL. 10, NO. 23, PAGES 2981-2992 *

Also Published As

Publication number Publication date
WO1999061040A3 (en) 2000-01-27
CA2329757A1 (en) 1999-12-02
WO1999061040A9 (en) 2001-02-01
SI1079843T1 (sl) 2007-10-31
CN1187084C (zh) 2005-02-02
DE69935853D1 (de) 2007-05-31
BR9911067A (pt) 2001-02-06
NZ508317A (en) 2004-01-30
EA004145B1 (ru) 2004-02-26
WO1999061040A2 (en) 1999-12-02
CZ20004358A3 (cs) 2002-01-16
HUP0202048A3 (en) 2006-11-28
EA200001092A1 (ru) 2001-06-25
EP1079843B1 (en) 2007-04-18
DE69935853T2 (de) 2008-01-10
EE04581B1 (et) 2006-02-15
ES2285841T3 (es) 2007-11-16
HUP0202048A2 (en) 2002-10-28
NO20005883L (no) 2001-01-17
PT1079843E (pt) 2007-06-26
NO20005883D0 (no) 2000-11-21
ATE359804T1 (de) 2007-05-15
EE200000685A (et) 2002-04-15
EP1079843A2 (en) 2001-03-07
DK1079843T3 (da) 2007-07-30
JP2002516287A (ja) 2002-06-04
CZ296262B6 (cs) 2006-02-15
CA2329757C (en) 2013-11-19
PL345946A1 (en) 2002-01-14
CN1310625A (zh) 2001-08-29
TR200003432T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
SG117434A1 (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
NO992282D0 (no) Benzonaftyridiner som bronkialterapentika
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
MXPA02004701A (es) Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ZA966577B (en) Pharmaceutical composition.
EP1060744A4 (en) AGENT FOR PREVENTING / TREATING OSTEOPOROSIS
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
WO2001070093A3 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
EP1584333A3 (en) Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
WO2002051415A3 (fr) Utilisation de chelateurs dans le traitement des maladies a prions